Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Files An 8-K Other Events

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Files An 8-K Other Events
Item 8.01. Other Events.

On March 25, 2020, Infinity Pharmaceuticals, Inc., issued a press release announcing that the U.S. Food and Drug Administration has granted Fast Track designation for IPI-549 in combination with nivolumab for the treatment of advanced urothelial cancer. The full text of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained on the websites referenced in the press release is not incorporated herein.
Item 9.01. Financial Statements and Exhibits.
(d) The following exhibit is included in this report:
INFINITY PHARMACEUTICALS, INC. Exhibit
EX-99.1 2 a32520pressrelease.htm EXHIBIT 99.1 Exhibit Exhibit 99.1Infinity Receives Fast Track Designation for IPI-549 in Combination with the Checkpoint Inhibitor Opdivo for the Treatment of Advanced Urothelial CancerCAMBRIDGE,…
To view the full exhibit click here

Story continues below

About Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.

An ad to help with our costs